DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Micardis® plus (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

Study to evaluate efficacy and tolerability of Micardis plus under usual daily-practice prescribing-conditions

Clinical Details

Official title: Post-Marketing Surveillance Study Micardis Plus

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Change from baseline in morning blood pressure

Change from baseline in classification of blood pressure

Secondary outcome:

Number of patients with adverse drug reactions

Assessment of efficacy by investigator on 5-point scale

Assessment of tolerability by investigator on a 5-point scale

Change from baseline in heart rate

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adult (Age >= 18 years) males and females for whom a medical antihypertensive therapy

is indicated Exclusion Criteria:

- Age < 18 years

Locations and Contacts

Additional Information

Starting date: June 2002
Last updated: September 11, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017